CoMentis is approaching the treatment of central nervous system disorders from many angles. The company was founded on its continuing work in the BACE field for the treatment of Alzheimer’s disease. Inhibitors of this key enzyme may offer the first disease-modifying treatment for Alzheimer’s disease.
The company also has a joint venture with Anvyl, LLC named Alpharmagen. Alpharmagen is working on agonists and positive allosteric modulators (PAMs) of the α7 nicotinic acetylcholine receptor (nAChR). Drugs targeting this receptor have already shown positive clinical results in Alzheimer’s and schizophrenia. Alpharmagen’s first joint development candidate, APN1125, an α7 nAChR agonist, entered human clinical trials in 2015.